Goldland Holdings Co. (GHDC)Announces New Transfer Agent and Signs “Letter of Intent“

Toronto, Ontario- March 30, 2016- Goldland Holdings Co., (GHDC.OTCPINK) announces that effective immediately the Company retained Transfer Online, Inc., Portland, Oregon, as its new stock transfer agent, www.transferonline.com.

Further, Goldland Holdings Co., announces it signed a revised letter of intent with Centro de Entretenimiento y Diversion Mombacho S.A., a Nicaraguan company.

Mr. Paul Parliament, CEO, stated, “ The executives are very pleased to be working with Transfer Online, a highly regarded industry leading transfer agent, which will greatly streamline GHDC’s operations going forward.  Also, now that we are a fully reporting and compliant company, this revised ‘Letter of Intent’ which has been sent to the company’s  lawyer to be formalized, allows us to complete the closing of the first of several business transactions. “

Upon formal documentation being completed, a FORM 8-K will be filed with the US SEC, detailing the transaction.

As the Company continues to progress with formalizing pending business arrangements and building new business relationships, management will update shareholders and other interested parties on its activities.

Goldland Holdings Co. would once again like to thank its shareholders for their patience throughout the past year.

For further information about this release, contact Kara Craig, YES  INTERNATIONAL, 757-306-6090, yes@yesinternational.com.

About Goldland Holdings Co:

Goldland Holdings Co. (OTC-PINK: GHDC) is a diversified Company, (holding gold and silver mining properties in North America, and casino equipment in South America) with a growth strategy driven by mergers, acquisitions, and new ventures. This will result in a multi-divisional, financially viable and profitable wholly-owned subsidiary model company.

Goldland Holdings Co. cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

Predictive Technology Group, Inc.’s (PRED) Subsidiary Predictive Therapeutics Receives Notice of Allowance from the United States Patent and Trademark Office on Spine Deformity Diagnostic and Bio-Implant

Notice of Allowance Positively impacts Company’s Pipeline of Diagnostic Tests and Companion Treatment Technologies

Salt Lake City, UT — (March 21, 2016) – Predictive Technology Group, Inc. (OTCPINK:PRED), a life sciences technology holding company, announced its subsidiary Predictive Therapeutics received a ‘Notice of Allowance’ from the United States Patent and Trademark Office.  

Mike Schramm, Predictive Therapeutics’ Director of Intellectual Property, said, “We are pleased that the USPTO examiner agreed with the Patent Trial and Appeal Board and issued a ‘Notice of Allowance’ for all twenty pending claims of the ‘105 application. The claims of the ‘105 application build on previously issued US patents 8,123,787 and 8,641,738 to which ‘105 claims priority and further bolster PRED’s Intellectual Property position.”

Bradley Robinson, PRED’s CEO added, “PRED is excited to move forward with its spinal deformity tests and begin development work on companion therapeutics. This allowance is confirmation of our intellectual property strategy relating to the diagnostic tests and companion therapeutic candidates in our R&D pipeline. We are especially pleased to move our spine diagnostics and related therapeutics one step closer to providing surgeons better insights into the exact cause of their patients’ spine issues and ability to determine the best course of care for patients.”

PRED’s subsidiary Predictive Therapeutics strives to provide its surgeon customers with the highest quality predictive diagnostics and treatment solutions that can ultimately benefit their patients.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent effectively and treat diseases.

For further information contact  Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 yes@yesinternational.com, www.yesinternational.com,  www.predictivetechnologygroup.com and/or www.predrx.com.

 Forward-Looking Statements

 To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

GOLDLAND HOLDINGS CO. (GHDC) REPORTS BEING CURRENT ON ITS U.S. SEC FILINGS, AND UPGRADED TO “CURRENT” STATUS OTCMARKETS.COM

Toronto, Ontario- March 11, 2016- GoldLand Holdings Co. (OTCPINK:GHDC) is pleased to announce that it has filed all past due filings with the U.S. SEC. In turn, the Company is now fully reporting under the 1934 Act.

OTCMARKETS.COM upgraded the trading status of the Company’s stock, GHDC, to “Current” issuer.

Mr. Paul Parliament, Chairman, and CEO states, “This is a great milestone for the Company.  I would like to thank all of the management team and professional service providers for their resilience and dedication to accomplish these filings.  Being fully reporting and having ‘CURRENT’ status gives the Company solid credibility within the investment communities. With this step now complete it will allow us to concentrate fully on the building of this company through the solidification of the many business relationships that have been established over the past year.”

GHDC intends to file the OTCMARKETS.COM application to uplistthe Company’s trading platform from “PINKSHEET CURRENT” to OTCQB.

The Company would like to thank our shareholders for their patience during this process, and as the Company progresses with its business operations, updates will follow in a timely manner. Management is currently in final contract negotiations which will complete the first of several planned business ventures that are intended to close in a timely manner.

For further information about this release, contact Kara Craig, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com.

About GoldLand Holdings Co:

GoldLand Holdings Co. (OTC-PINK: GHDC) is a diversified Company, (holding gold and silver mining properties in North America, and casino equipment in South America) with a growth strategy driven by mergers, acquisitions, and new ventures. This will result in a multi-divisional, financially viable and profitable wholly-owned subsidiary model company.

GoldLand Holdings Co. cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

ReNovo Biotech Partners with Nexus CMF to Distribute Allograft Products

Amniotic Derived Tissues Promise New Treatment Options for CMF Surgeons

Salt Lake City, UT – March 3, 2016 – ReNovo Biotech, Inc. (ReNovo), a cellular, tissue and regenerative medicine company, today announced an exclusive partnership agreement with Salt Lake City based Nexus CMF to distribute ReNovo’s allograft tissue products to craniomaxillofacial surgeons in the United States.

“Nexus CMF is committed to providing a versatile array of treatment solutions that enable CMF healthcare providers and health systems opportunities to improve overall patient outcomes,” said Jared Crocker, Nexus CMF’s President, “These amniotic derived products are unique in their quality and content. Nexus CMF is excited to provide our surgeon customers with this singular and minimally invasive alternative for their patients.”

Eric Olson, ReNovo Biotech’s CEO added, “Nexus CMF is a great partner for the ReNovo Biotech brand. They have the scale, infrastructure, reputation, clinical experience and complementary product portfolio to make ReNovo Biotech’s products a market leader in the United States. We are pleased that Nexus CMF recognized the quality, innovation and need of our products.”

ReNovo Biotech is focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.

Nexus CMF is a medical device company specializing in treatments for temporomandibular joint disorders. In addition to the newly launched allograft tissue products, the company offers a proprietary TMJ arthroscopy system and the only partial TMJ prosthesis approved by the FDA. It is also the only company in the United States to manufacture both stock and patient-specific TMJ prostheses.

The distribution agreement may be expanded with additional products and territories in the future. The terms of the agreement were not disclosed.

ReNovo Biotech recently announced the signing of a Letter of Intent to be acquired by Predictive Technology Group, Inc. (OTCPINK: PRED). This pending acquisition will in no way interfere with this partnership agreement with Nexus CMF.

For further information contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com, www.yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.

About ReNovo Biotech, Inc.

ReNovo Biotech, Inc. a cellular and regenerative medicine company is focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.

Predictive Technology Group, Inc. (PRED) Announces “Letter of Intent” to Acquire ReNovo Biotech, Inc.

Company Seeks to Combine Use of Molecular Diagnostics with Stem Cell Technologies

Salt Lake City, UT – March 02, 2016 – Predictive Technology Group, Inc. (OTCPINK: PRED), through its wholly-owned subsidiary Predictive Therapeutics, Inc., announces that the Company has entered into a “Letter of Intent” to acquire ReNovo Biotech, Inc.

PRED through this acquisition gains access to ReNovo Biotech’s cellular, tissue, biomaterial and regenerative medicine products, R&D, sales/marketing expertise, distribution channels and product candidates. With the execution of this “Letter of Intent,” PRED expects to finalize and sign a definitive agreement after completing due diligence.

Bradley Robinson, CEO, Predictive Therapeutics, said, “We are very excited to announce our letter of intent to acquire ReNovo Biotech. This acquisition is one of the first steps in PRED’s strategy to expand its portfolio of products and technologies that can be used as companion treatment solutions to our molecular diagnostic tests. This will also allow us to begin clinical trials for the treatment of debilitating diseases with allogeneic and autologous stem cell products.”

Eric Olson, ReNovo Biotech’s CEO states, “We are pleased with the potential to be acquired by the publicly traded company, PRED.  Utilizing PRED’s public experience and its umbrella of unique technologies gives ReNovo a multitude of opportunities that might not otherwise exist. Stem cells can be evaluated and assayed, guaranteeing those specific disease markers are NOT present prior to expanding particular cell lines used in ReNovo’s products. We believe that combining the use of molecular diagnostics with stem cell technologies will be a major breakthrough in our understanding of how stem cells are used for clinical applications.”

Predictive Technology Group, Inc., through its wholly owned subsidiary Predictive Therapeutics, Inc., believes that a ReNovo Biotech, Inc. acquisition can bring immediate revenue and cash flow from ReNovo’s distribution channels and private label partnerships.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

About ReNovo Biotech, Inc.

ReNovo Biotech, Inc. a cellular and regenerative medicine company is focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.